AGIO - Agios Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
49.31
+0.81 (+1.68%)
As of 2:52PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close48.50
Open48.56
Bid49.17 x 800
Ask49.19 x 1000
Day's Range48.28 - 49.43
52 Week Range41.63 - 94.39
Volume294,413
Avg. Volume579,648
Market Cap2.895B
Beta (3Y Monthly)2.24
PE Ratio (TTM)N/A
EPS (TTM)-5.99
Earnings DateAug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est81.63
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    Agios to Webcast Conference Call of Second Quarter 2019 Financial Results on August 1, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August 1, 2019 at 8:00 a.m. ET to report its second quarter 2019 financial results and other business highlights. A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology.

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

    Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AGIO is favorable, with net inflows of $5.05 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire17 days ago

    Agios Announces Orlando Oliveira Appointed as Senior Vice President and General Manager, International

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Orlando Oliveira to the role of senior vice president and general manager, international, who will be responsible for building and leading the company’s operations outside of the U.S. in support of the expected launch of TIBSOVO® in Europe and potentially other select markets. Mr. Oliveira will be based in Zug, Switzerland and report to Jackie Fouse, Ph.D., chief executive officer at Agios.

  • Agios (AGIO) Catches Eye: Stock Jumps 5.4%
    Zackslast month

    Agios (AGIO) Catches Eye: Stock Jumps 5.4%

    Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?
    Simply Wall St.last month

    Volatility 101: Should Agios Pharmaceuticals (NASDAQ:AGIO) Shares Have Dropped 50%?

    Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

  • Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?
    Insider Monkeylast month

    Is Agios Pharmaceuticals Inc (AGIO) Going to Burn These Hedge Funds?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]

  • GlobeNewswirelast month

    Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, June 11, 2019 at 2:40 p.m. PT. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.

  • Life sciences VC firm Third Rock raises $770M in its largest round ever
    American City Business Journalslast month

    Life sciences VC firm Third Rock raises $770M in its largest round ever

    One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.

  • GlobeNewswirelast month

    Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019

    Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the planned retirement of its chief scientific officer, Scott Biller, Ph.D. Dr. Biller will retire from his CSO position at the end of 2019 and continue to serve as a strategic advisor through the end of 2020. Under his leadership, the team has built a robust preclinical pipeline and advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage clinical programs,” said Jackie Fouse, Ph.D., chief executive officer at Agios. “It has been a privilege and honor to be a part of the Agios team for nearly a decade and to work toward our shared vision of making a meaningful impact on the lives of patients,” said Dr. Biller.

  • GlobeNewswirelast month

    Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy

    – With Longer Follow Up, CR+CRh Rate Increased to 70% and CR Rate Increased to 61% in the Phase 1 Study of TIBSOVO® in Combination with Azacitidine – – Phase 1 Data of Single.

  • Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?
    Zacks2 months ago

    Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?

    Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
    Zacks2 months ago

    Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

    Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.

  • Benzinga2 months ago

    The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 15) Applied Therapeutics Inc (NASDAQ: APLT ) (debuted on ...

  • Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight
    Insider Monkey2 months ago

    Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight

    Although it is rapidly approaching 13F season and traders are closely watching oil stocks due to the rising Middle East tensions, several stocks such as Alibaba Group Holding Limited (NYSE:BABA), Altaba Inc. (NASDAQ:AABA), Cisco Systems, Inc. (NASDAQ:CSCO), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Virtusa Corporation (NASDAQ:VRTU) are in the spotlight for various reasons. Let's analyze why traders are watching each stock […]

  • CNBC2 months ago

    Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more

    Shares of Cisco Systems CSCO rose more than 2.5% in extended trading Wednesday after the networking hardware company reported better-than-expected fourth quarter results. The company also gave strong guidance for the fourth quarter with estimated earnings per share and revenue both coming in higher than Refinitiv consensus estimates. Farfetch reported a loss of 22 cents per share, worse than the expected loss of 16 cents per share, and revenue of $174.1 million, higher than the expected $171.1 million, according to Refinitiv consensus estimates.

  • GlobeNewswire2 months ago

    Agios to Present Clinical Data from its IDH Program at ASCO

    CAMBRIDGE, Mass., May 15, 2019 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.

  • GlobeNewswire2 months ago

    Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

    – TIBSOVO® Demonstrated a Statistically Significant Improvement in Progression-Free Survival Compared to Placebo – – Safety Profile Consistent with Published Phase 1 Data in.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AGIO earnings conference call or presentation 2-May-19 12:00pm GMT

    Q1 2019 Agios Pharmaceuticals Inc Earnings Call